Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- City of Hope at Irvine Lennar
Irvine, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, United States
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
- Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
- Siteman Cancer Center-South County
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
- Ut Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 May 2021
- Primary completion
- 1 Jul 2026
- Completion
- 1 Jul 2026
- Last update posted
- 22 Jun 2026
- Registered enrollment
- 48
- Registry id
- NCT04595747
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.